What question did this study set out to answer?

To evaluate the antitumor efficacy, toxicity profiles, and survival outcomes of mitoxantrone compared with cisplatin in patients with primary hepatocellular carcinoma.

November 1, 1987CancerOpen Access

A random phase II study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma: An ECOG study

View Full Paper

Ask AI

Bookmark

Authors

GFG FalksonUniversity of Pretoria LRLouise RyanUniversity of Technology Sydney LJLewis A. JohnsonBoston University

Discussion

Member takes

Implication

Randomized trial shows poor antitumor activity and a 14-week median survival with mitoxantrone or cisplatin in hepatocellular carcinoma, indicating limited efficacy for both agents.

Key Points

To evaluate the antitumor efficacy, toxicity profiles, and survival outcomes of mitoxantrone compared with cisplatin in patients with primary hepatocellular carcinoma.
Randomized phase II trial evaluating mitoxantrone versus cisplatin in 86 enrolled patients with primary liver cancer (N=69 eligible; 61% North American, 39% South African).
Assessed tumor response rates, severe toxicities, and overall survival using a proportional hazards model adjusted for clinical baseline variables.
Objective tumor response was limited to two partial responses in the cisplatin arm, yielding true response rates of less than 8% for mitoxantrone and less than 17% for cisplatin (95% CI).
Median survival was 14 weeks for both arms, and 21 of 69 patients experienced severe, life-threatening, or fatal toxicities.
Impaired performance status, disease symptoms, elevated bilirubin, hepatomegaly, and clinical cirrhosis significantly predicted poorer survival, explaining regional outcome differences.

Cite This Study

Falkson et al. (1987) studied this question.

synapsesocial.com/papers/6a87cf7370098fa105bb586c https://doi.org/10.1002/1097-0142(19871101)60:9<2141::aid-cncr2820600903>3.0.co;2-4

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial shows poor antitumor activity and a 14-week median survival with mitoxantrone or cisplatin in hepatocellular carcinoma, indicating limited efficacy for both agents.

A random phase II study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma: An ECOG study

Discussion

Member takes

Implication

Key Points

Cite This Study

A random phase II study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma: An ECOG study

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider